Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bashar Katirji

Showing results (81-90 of 85) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 85 results.
Muscle & Nerve|October 2, 2020
Risk factors for amyotrophic lateral sclerosis: A regional United States case-control studyAngeline S Andrew, Walter G Bradley, Daniel Peipert, et al.
Neuroepidemiology|April 26, 2021
The Incidence of Amyotrophic Lateral Sclerosis in Ohio 2016-2018: The Ohio Population-Based ALS RegistryAngeline S Andrew, Erik P Pioro, Meifang Li, et al.
Neurology|July 3, 2020
Minimal manifestation status and prednisone withdrawal in the MGTX trialIkjae Lee, Hui-Chien Kuo, Inmaculada B Aban, et al.
The New England Journal of Medicine|August 11, 2016
Randomized Trial of Thymectomy in Myasthenia GravisGil I Wolfe, Henry J Kaminski, Inmaculada B Aban, et al.
The Lancet. Neurology|January 30, 2019
Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trialGil I Wolfe, Henry J Kaminski, Inmaculada B Aban, et al.
Pageof 9

Showing results (81-90 of 85) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 85 results.
Muscle & Nerve|October 2, 2020
Risk factors for amyotrophic lateral sclerosis: A regional United States case-control studyAngeline S Andrew, Walter G Bradley, Daniel Peipert, et al.
Neuroepidemiology|April 26, 2021
The Incidence of Amyotrophic Lateral Sclerosis in Ohio 2016-2018: The Ohio Population-Based ALS RegistryAngeline S Andrew, Erik P Pioro, Meifang Li, et al.
Neurology|July 3, 2020
Minimal manifestation status and prednisone withdrawal in the MGTX trialIkjae Lee, Hui-Chien Kuo, Inmaculada B Aban, et al.
The New England Journal of Medicine|August 11, 2016
Randomized Trial of Thymectomy in Myasthenia GravisGil I Wolfe, Henry J Kaminski, Inmaculada B Aban, et al.
The Lancet. Neurology|January 30, 2019
Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trialGil I Wolfe, Henry J Kaminski, Inmaculada B Aban, et al.
Pageof 9